(Q46345800)

English

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Stu

scientific article published on 25 September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

lymphoplasmacytic lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

C Buske

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

M Dreyling

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

H Eimermacher

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

H Wandt

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

B Metzner

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

R Fuchs

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

J Bittenbring

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

B Woermann

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

K Hohloch

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

G Hess

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

W-D Ludwig

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

J Schimke

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

S Schmitz

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

M Kneba

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

M Reiser

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

U Graeven

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

W Klapper

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

M Unterhalt

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

W Hiddemann

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

German Low-Grade Lymphoma Study Group

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

publication date

25 September 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

153-161

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818699%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

https://scigraph.springernature.com/pub.10.1038/leu.2008.261

0 references

Updated Kiel classification for lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining Waldenstrom's macroglobulinemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of the Third International Workshop on Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis and management of Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunocytoma: a retrospective analysis from St Bartholomew's Hospital-1972 to 1996.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended rituximab therapy in Waldenström's macroglobulinemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment for Waldenstrom's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis to evaluate the role of interferon in follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant interferon-alpha therapy in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.261

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46345800&oldid=1561079638"